Testosterone is commonly-recognized as the ‘master’ male hormone because it controls and directs the rate of a man’s sexual development. Testosterone also plays a key role in determining a man’s overall health and well-being. High levels of testosterone mean sexual, physical and mental energy, stamina and vitality. Low levels contribute to fatigue, premature aging and disease.
While testosterone levels naturally decline with age, a number of other lifestyle factors including stress, physical inactivity, over-training, lack of sleep, chronic illness, smoking, drinking and the use of prescription medications and drugs can also contribute to the onset of low testosterone.
Along with this decline in testosterone with age and lifestyle, many men also experience increases in the levels of estrogen. The result is a testosterone/estrogen imbalance that directly causes many of the debilitating health problems associated with normal aging. The vast majority of men are surprised to learn that estrogen (a ‘female’ hormone) is also present in their bodies. It is produced in very small amounts as a by-product of the testosterone conversion process. In fact, balanced levels of estrogen in men are essential to encourage a healthy libido, improved brain function, protect the heart and strengthen the bones.
But due to aging, body fat, hormonal replacement, pesticides, nutritional deficiencies, prescription medications and excessive alcohol intake many men experience high levels of estrogen which are detrimental to their health. In fact, studies have shown that the estrogen levels of the average 54-year-old man is higher than those of the average 59-year-old women! The end result is that these high levels of estrogen can cause reduced levels of testosterone, fatigue, loss of muscle tone, increased body fat, loss of libido and sexual function and an enlarged prostate.
In youth, small amounts of estrogen are used to reduce the cell-stimulating effects of testosterone. But when there is too little testosterone present, estrogen attaches to testosterone cell receptor sites throughout the body. Subsequently, as estrogen levels increase with age, testosterone is not able to stimulate the cells causing reduced sexual arousal and sensation as well the loss of libido. Other problems associated with excessive levels of estrogen include:
(1) The shut down of normal testicular production of testosterone. Excess estrogen can saturate testosterone receptors in the hypothalamus in the brain therefore reducing the signal sent to the pituitary gland. This in turn reduces the secretion of luteinizing hormone, which is necessary for the gonads to produce testosterone.
(2) Increasing the body’s production of sex hormone-binding globulin (SHBG). SHBG binds testosterone therefore reducing the amount of the clinical important free testosterone in the blood available to cell receptor sites.
(3) A reduced effectiveness of the testosterone replacement therapy due to excess aromatization of testosterone medications to estrogen.
(4) Long-term health risks including an increased risk of diabetes, heart disease, and some cancers.
The evidence is clear that it is essential for men who are concerned about healthy aging, who are suffering from symptoms of low testosterone or undergoing testosterone replacement therapy need to take aggressive action and assess their estrogen levels and reduce any excessive estrogen to a safe range.
Saliva testing is an excellent method to inexpensively test the important male hormones including estradiol, the most active form of estrogen. If testing shows that your estradiol levels are high and/or free testosterone levels are low or low normal, you are using testosterone or prohormone support, you desire increased abdominal fat loss or you want to protect your prostate the following protocol is suggested.
(1) Lose weight. Fat cells, especially in the abdominal region, produce the aromatase enzyme, which converts testosterone into estrogen.
(2) Reduce or eliminate alcohol consumption to enable your liver to better remove excess estrogens.
(3) Get 80-90 mg a day of zinc. Zinc functions as an aromatase inhibitor for some men.
(4) Increase the amount of cruciferous vegetables such as broccoli and cauliflower and flax these promote the liver to metabolize and excrete excess estrogen
(5) Reduce or eliminate and medications that you are regularly taking that may interfere with your healthy liver function. Common medications include NSAIDs (e.g. ibuprofen, acetaminophen, aspirin), the “statin” class of cholesterol lowering drugs, some heart and blood pressure medications, and some anti-depressants.
(6) Use a topical chrysin/ diindolin formula such as Anti-Estrogen SportsCreme ® by MedLean. This formula contains:
Extracts of Passiflora coerulea including chrysin: These naturally-occurring bioflavanoid (isoflavones) are potent inhibitors of aromatase, the enzyme that converts testosterone to estradiol. Along with the many other natural flavonoids that exist in a plant based diet including genistein, rutin, tea catechins, these extracts may contribute to the effectiveness of plant based diets for the prevention if cancer. They also have anti-oxidant, anti-inflammatory and anti-anxiety properties. Their direct effect on the neuroreceptors in the brain may create a calming effect in many men.
Note: Chrysin is poorly absorbed when taken orally, but the beneficial effects of this phytonutrient are seen when applied topically.
Di-Indole-Methane: An extract of cruciferous vegetables, DIM, acts to promote and support a favorable metabolism of estrogen and related hormones by enhancing the liver’s ability to metabolize estrogen to “weaker” 2-hydroxyestrone. DIM, may reduce prostate cancer incidence as it has been shown to stop human cancer cells from growing by (54-61%) and provoking the cells to self-destruct (apoptosis). DIM, also improves prostate function, enhances insulin sensitivity and increases abdominal fat loss.
Urtica Dioca:A special extract of this popular herb has been shown to increase bioavailable (free) testosterone levels by freeing it from SHBG – the testosterone-binding protein in the blood. In addition, it inhibits aromatase and protects the prostate by blocking the conversion of testosterone to DHT.
(7) If after six to eight weeks, the above protocol does not lower excess estradiol levels, then it is recommended that you try the prescription medicine Arimidex ® (anastrozole), a potent aromatase-inhibiting drug starting at the low dose of 0.5 mg, twice a week increasing to a maximum of 1.0 mg daily. Side effects from this medication is rare.
In conclusion: Testosterone is the ‘master’ male hormone but if you have too little or too much estrogen, you will never be able to look and feel your best.
- Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Walle UK, Galijatovic A, Walle T Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston 29425, USA. Biochem Pharmacol 1999 Aug 1;58(3):431-8
- Flavonoid inhibition of aromatase enzyme activity in human preadipocytes. Campbell DR, Kurzer MS Department of Food Science and Nutrition, University of Minnesota, St. Paul 55108, USA. J Steroid Biochem Mol Biol 1993 Sep;46(3):381-8
- Inhibition of human estrogen synthetase (aromatase) by flavones. Kellis JT Jr; Vickery LE Science, 225(4666):1032-4 1984 Sep 7
- Inhibition of aromatase activity by flavonoids. Jeong HJ, Shin YG, Kim IH, Pezzuto JM Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 60612, USA. Arch Pharm Res 1999 Jun;22(3):309-12
- Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: site-directed mutagenesis study. Kao YC, Zhou C, Sherman M, Laughton CA, Chen S Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA. Environ Health Perspect 1998 Feb;106(2):85-92
- Chrysin (5,7-di-OH-flavone), a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Medina JH, Paladini AC, Wolfman C, Levi de Stein M, Calvo D, Diaz LE, Pena C Instituto de Biologia Celular, Facultad de Medicina, Buenos Aires, Argentina. Biochem Pharmacol 1990 Nov 15;40(10):2227-31
- Inhibition of human estrogen synthetase (aromatase) by flavones. Kellis JT Jr, Vickery LE Science 1984 Sep 7;225(4666):1032-4
- Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. Wang, C., et al., J Steroid Biochem Mol Biol, 1994. 50(3-4): p. 205-12.
- Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids. Le Bail, J.C., et al., Cancer Lett, 1998. 133(1): p. 101-106.
- Aromatase inhibition by flavonoids. Ibrahim, A.R. and Y.J. Abul-Hajj, J Steroid Biochem Mol Biol, 1990. 37(2): p. 257-260.
- Effects of stinging nettle root extracts and their steroidal components on the Na+,K(+)-ATPase of the benign prostatic hyperplasia. Hirano T, Homma M, Oka K Department of Clinical Pharmacology, Tokyo College of Pharmacy, Japan. Planta Med 1994 Feb;60(1):30-3
- The inhibiting effects of Urtica dioica root extracts on experimentally induced prostatic hyperplasia in the mouse. Lichius JJ, Muth C Institut fur Pharmazeutische Biologie, Philipps-Universitat, Marburg, Germany. Planta Med 1997 Aug;63(4):307-10
- The micronutrient indole-3-carbinol: implications for disease and chemoprevention. Shertzer HG, Senft AP. Department of Environmental Health and Center for Environmental Genetics, University of Cincinnati College of Medicine, OH 45267 Drug Metabol Drug Interact 2000;17(1-4):159-88
- Phytochemicals as modulators of cancer risk. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. Strang Cancer Research Laboratory, New York, NY 10021 Adv Exp Med Biol 1999;472:207-21
- Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)-3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Chang YC, Riby J, Chang GH, Peng BC, Firestone G, Bjeldanes LF. Division of Nutritional Sciences and Toxicology, University of California, Berkeley 94720, USA Biochem Pharmacol 1999 Sep 1;58(5):825-34
- An updated review of environmental estrogen and androgen mimics and antagonists. Sonnenschein C, Soto AM. J Steroid Biochem Mol Biol 1998 Apr;65(1-6):143-50
- Exposure with the environmental estrogen bisphenol A disrupts the male reproductive tract in young mice. Takao T, et al. Life Sci 1999;65(22):2351-7
- Testicular cancer and occupational exposures with a focus on xenoestrogens in polyvinyl chloride plastics. Ohlson CG, Hardell L. Chemophere 2000 May-Jun;40(9-11):1277-82
- Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. Mauras N, et al. J Clin Endocrinol Metab 1998 Jun;83(6):1886-92
- Research needs for the risk assessment and environmental effects of endocrine disruptors: A report of the U.S. EPA-sponsored workshop. Kavlock R.J., et al. Environ Health Persp 1996 104 Suppl 4:714-740
- Toxic responses of the nervous system. Anthony DC, Graham DG. Basic Science of Poisins p 407-429
- Synergistic effects of environmental estrogens. Report withdrawn. McLachlan JA. Science 1997 277:462-463
- Brain aromatase and 5-alpha reductase, regulatory behaviors and testosterone levels in adult rats on phytoestrogen diets. Weber, K.S., et al., Proc Soc Exp Biol Med, 1999. 221(2): p. 131-135.
- Hypophyseal-gonadal system during male aging. Moroz EV, Verkhratsky NS Arch Gerontol Geriatr 1985 Apr;4(1):13-9
- Age variation of the 24-hour mean plasma concentrations of androgens, estrogens, and gonadotropins in normal adult men. Zumoff B, Strain GW, Kream J, O’Connor J, Rosenfeld RS, Levin J, Fukushima DK J Clin Endocrinol Metab 1982 Mar;54(3):534-8
- Age-related changes of plasma steroids in normal adult males. Drafta D, Schindler AE, Stroe E, Neacsu E J Steroid Biochem 1982 Dec;17(6):683-7
- Changes in the pituitary-testicular system with age. Baker HW, Burger HG, de Kretser DM, Hudson B, O’Connor S, Wang C, Mirovics A, Court J, Dunlop M, Rennie Clin Endocrinol (Oxf) 1976 Jul;5(4):349-72
- Androgen and estrogen production in elderly men with gynecomastia and testicular atrophy after mumps orchitis. Aiman J, Brenner PF, MacDonald PC J Clin Endocrinol Metab 1980 Feb;50(2):380-6
- The influence of aging on plasma sex hormones in men: the Telecom Study. Simon D, Preziosi P, Barrett-Connor E, Roger M, Saint-Paul M Am J Epidemiol 1992 Apr 1;135(7):783-91
- Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Ferrini RL, Barrett-Connor E Am J Epidemiol 1998 Apr 15;147(8):750-4
- Estrogen-androgen levels in aging men and women: therapeutic considerations. Greenblatt RB, Oettinger M, Bohler CS J Am Geriatr Soc 1976 Apr;24(4):173-8
- The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Zmuda JM, Fahrenbach MC, Younkin BT, Metabolism 1993 Apr;42(4):446-50
- Origin of estrogen in normal men and in women with testicular feminization. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK J Clin Endocrinol Metab 1979 Dec;49(6):905-16
- Familial gynecomastia with increased extra-glandular aromatization of plasma carbon19-steroids. Berkovitz GD, Guerami A, Brown TR, MacDonald PC, Migeon CJ J Clin Invest 1985 Jun;75(6):1763-9
- The association of hyperestrogenemia with coronary thrombosis in men. Phillips GB, Pinkernell BH, Jing TY Arterioscler Thromb Vasc Biol 1996 Nov;16(11):1383-7
- Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. De Pergola G, De Mitrio V, Sciaraffia M, Pannacciulli N, Minenna Metabolism 1997 Nov;46(11):1287-93
- Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Suzuki K, Ito K, Ichinose Y, Kurokawa K, Suzuki T, Scand J Urol Nephrol 1995 Mar;29(1):65-8
- Estrogen formation in human prostatic tissue from patients with and without benign prostatic hyperplasia. Stone NN, Fair WR, Fishman J Prostate 1986;9(4):311-8
- Roles of estrogen and SHBG in prostate physiology. Farnsworth WE Prostate 1996 Jan;28(1):17-23
- The effect of extracts of the roots of the stinging nettle (Urtica dioica) on the interaction of SHBG with its receptor on human prostatic membranes. Hryb DJ, Khan MS, Romas NA, Rosner W Planta Med 1995 Feb;61(1):31-2
- Direct effects of estrogens on the endocrine function of the mammalian testis. Moger WH Can J Physiol Pharmacol 1980 Sep;58(9):1011-22
- Direct inhibitory effect of estrogen on the human testis in vitro. Namiki M, Kitamura M, Nonomura N, Sugao H, Nakamura M, Arch Androl 1988;20(2):131-5
- The acute effect of estrogens on testosterone production appears not to be mediated by testicular estrogen receptors Damber JE; Bergh A, Daehlin L, Ekholm C, Selstam G Mol Cell Endocr 31 (1). 1983. 105-116.
- The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Zmuda JM; Fahrenbach MC; Younkin BT; Bausserman LL; Metabolism (United States) Apr 1993, 42 (4) p446-50.
- Levels of sex hormone-binding globulin and corticosteroid-binding globulin mRNAs in corpus luteum of human subjects: correlation with serum steroid hormone levels. Misao R, Nakanishi Y, Fujimoto J, Iwagaki S, Tamaya T Gynecol Endocrinol 1999 Apr;13(2):82-8
- Effects of ethinyloestradiol on plasma levels of pituitary gonadotrophins, testicular steroids and sex hormone binding globulin in normal men. Van Look PF, Frolich M Clin Endocrinol (Oxf) 1981 Mar;14(3):237-43
- Testosterone and depression in aging men. Seidman SN, Walsh BT Am J Geriatr Psychiatry 1999 Winter;7(1):18-33
- Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D J Clin Endocrinol Metab 1999 Feb;84(2):573-7
- Evidence for hyperestrogenemia as the link between diabetes mellitus and myocardial infarction. Phillips GB Am J Med 1984 Jun;76(6):1041-8
- Serum estrogen levels in men with acute myocardial infarction. Klaiber EL, Broverman DM, Haffajee CI, Hochman JS, Am J Med 1982 Dec;73(6):872-81
- Variability in plasma oestrogen concentrations in men with a myocardial Infarction. Lindholm J, Eldrup E, Winkel P Dan Med Bull 1990 Dec;37(6):552-6
- Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls. Marques-Vidal P, Sie P, Cambou JP, J Clin Endocrinol Metab 1995 Jun;80(6):1794-8
- The determination of serum estradiol, testosterone and progesterone in acute myocardial infarction. Aksut SV, Aksut G, Karamehmetoglu A, Oram E Jpn Heart J 1986 Nov;27(6):825-37
- Serum estradiol and testosterone levels following acute myocardial infarction in men. Tripathi Y, Hegde BM Indian J Physiol Pharmacol 1998 Apr;42(2):291-4
- Oestradiol levels in diabetic men with and without a previous myocardial infarction. Small M, MacRury S, Beastall GH Q J Med 1987 Jul;64(243):617-23
- Direct effects of estrogens on the endocrine function of the mammalian testis. Moger WH Can J Physiol Pharmacol 1980 Sep;58(9):1011-22
- The acute effect of estrogens on testosterone production appears not to be mediated by testicular estrogen receptors Damber J E; Bergh A; Daehlin L; Ekholm C; Mol Cell Endocr 31 (1). 1983. 105-116.
- The effect of testosterone aromatization on high-density lipoprotein cholesterol level and postheparin lipolytic activity. Zmuda JM; Fahrenbach MC; Younkin BT; Metabolism (United States) Apr 1993, 42 (4) p446-50.
- Fat tissue a steroid reservoir and site of steroid metabolism. Deslypere J P; Verdonck L; Vermeulen A J Clin Endocrinol Metab 61 (3). 1985. 564-570.
- Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. Gray A, Feldman HA, McKinlay JB, Longcope C J Clin Endocrinol Metab 1991 Nov;73(5):1016-25
- The influence of age, alcohol consumption, and body build on gonadal function in men. Sparrow D, Bosse R, Rowe JW J Clin Endocrinol Metab 1980 Sep;51(3):508-12